Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;22(2):519-531.
doi: 10.1111/ajt.16817. Epub 2021 Sep 13.

Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation

Emily A Saunders  1 , Bastian Engel  1 , Anne Höfer  1 , Björn Hartleben  2 , Florian W R Vondran  3 , Nicolas Richter  3 , Andrej Potthoff  1 , Steffen Zender  1 , Heiner Wedemeyer  1 , Elmar Jaeckel  1 , Richard Taubert  1
Affiliations
Free article

Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation

Emily A Saunders et al. Am J Transplant. 2022 Feb.
Free article

Abstract

Graft survival beyond year 1 has not changed after orthotopic liver transplantation (OLT) over the last decades. Likewise, OLT causes comorbidities such as infection, renal impairment and cancer. We evaluated our single-center real-world individualized immunosuppression program after OLT, based on 211 baseline surveillance biopsies (svLbx) without any procedural complications. Patients were classified as low, intermediate and high rejection risk based on graft injury in svLbx and anti-HLA donor-specific antibodies. While 32% of patients had minimal histological inflammation, 57% showed histological inflammation and 23% advanced fibrosis (>F2), which was not predicted by lab parameters. IS was modified in 79% of patients after svLbx. After immunosuppression reduction in 69 patients, only 5 patients showed ALT elevations and three of these patients had a biopsy-proven acute rejection, two of them related to lethal comorbidities. The rate of liver enzyme elevation including rejection was not significantly increased compared to a svLbx control cohort prior to the initiation of our structured program. Immunosuppression reduction led to significantly better kidney function compared to this control cohort. In conclusion, a biopsy guided personalized immunosuppression protocol after OLT can identify patients requiring lower immunosuppression or patients with graft injury in which IS should not be further reduced.

Keywords: clinical research/practice; immunosuppression/immune modulation; immunosuppressive regimens - maintenance; immunosuppressive regimens - minimization / withdrawal; kidney failure/injury; liver allograft function/dysfunction; liver transplantation/hepatology; rejection: subclinical.

PubMed Disclaimer

References

REFERENCES

    1. Watt KDS, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010;10(6):1420-1427.
    1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931-940.
    1. Rana A, Ackah RL, Webb GJ, et al. No gains in long-term survival after liver transplantation over the past three decades. Ann Surg. 2019;269(1):20-27.
    1. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57(3):675-688.
    1. Clajus C, Hanke N, Gottlieb J, et al. Renal comorbidity after solid organ and stem cell transplantation. Am J Transplant. 2012;12(7):1691-1699.

Publication types

Substances